Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 31; no. 2-3; pp. 267 - 270
• Main Authors: De Pas, Tommaso, de Braud, Filippo, Mandalà, Mario, Curigliano, Giuseppe, Catania, Chiara, Ferretti, Gianluigi, Sozzi, Pietro, Solli, Piergiorgio, Goldhirsch, Aron
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01.02.2001; Elsevier Science
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Cisplatin; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cisplatin - therapeutic use; Deoxycytidine - analogs & derivatives; Deoxycytidine - pharmacology; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Medical sciences; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Paclitaxel - pharmacology; Pharmacology. Drug treatments; Second-line chemotherapy; Survival Analysis; Vinblastine - administration & dosage; Vinblastine - adverse effects; Vinblastine - analogs & derivatives; Vinblastine - therapeutic use; Vinorelbine; Second-line chemotherapy; Lung cancer; Cisplatin; Vinorelbine; Antineoplastic agent; Human; Lung disease; Respiratory disease; Treatment efficiency; Malignant tumor; Bronchopulmonary; Alkylating agent; Alkaloid; Chemotherapy; Treatment; Bronchus disease; Advanced stage; Non small cell carcinoma; Platinum II Complexes
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/S0169-5002(00)00176-8

The aim of the study was to evaluate the activity of cisplatin (CDDP) plus vinorelbine (VNR) in patients with advanced non-small cell lung cancer (NSCLC) progressing after paclitaxel plus gemcitabine. Treatment consisted of CDDP 80 mg/m2 administered on day 1 and VNR 25 mg/m2 administered on day 1 and 8, repeated every 3 weeks. Nine patients who relapsed after partial response and eight patients refractory to prior CT received a minimum of two treatment cycles: three patients achieved a PR (18%; 95% CI: 4–43%), four had stable disease and 10 had disease progression. All responses were observed among the nine patients responsive to prior treatment. Median survival was 35 weeks. No patients required dose-reduction, treatment discontinuation or delay because of toxicity. Our results indicate a reasonable antitumor efficacy and no relevant toxicity of a second-line CDDP-based chemotherapy in patients with advanced NSCLC. We recommend the use of this regimen for patients not refractory to primary treatment.